Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development expenses ...
The stock of Eli Lilly (LLY) has been upgraded by independent investment bank Leerink Partners as its weight-loss medications ...
Great stock investing opportunities often come in two forms: undervalued stocks at an inflection point, and high-growth-at-a-reasonable-price shares. In my opinion, Novo Nordisk (NVO) stock offers the ...
Zacks Investment Research on MSN
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite ...
Eli Lilly's stock is overvalued by around 27% despite its success in developing drugs for diabetes and obesity. LLY has strong financial performance with steady revenue growth and profitability ...
Eli Lilly's eyewatering upsurge this year was upended by its double-slashed full-year 2024 guidance following the Q3 earnings update this morning. The slight Q3 revenue miss continues to highlight ...
Healthcare companies are not completely immune to macro pressures but are generally more resilient compared to companies in other sectors. This is because of the essential nature of medicines and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback